Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $51.74B | 40x | 0.74 | $840.87 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
| Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $48.33B | 39.5x | -0.28 | $68.14 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.2% Upside | Upgrade to Pro+ | |
| BeOne Medicines DRC | NASDAQ | Healthcare | Biotechnology & Medical Research | $34.38B | 121.1x | 0.85 | $319.94 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.7% Upside | Upgrade to Pro+ | |
| Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | $31.70B | -22.9x | 1.68 | $146.64 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
| Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | $30.39B | -25.7x | 0.38 | $152.62 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.5% Upside | Upgrade to Pro+ | |
| IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | $29.84B | 22.5x | 4.61 | $178.10 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.4% Upside | Upgrade to Pro+ | |
| BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | $25.18B | -18x | 0.27 | $99.47 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.9% Upside | Upgrade to Pro+ | |
| Wuxi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $19.53B | 25.1x | 0.57 | $9.46 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $17.83B | 18.8x | -1.5 | $29.30 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
| Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $16.17B | -11.2x | 0.04 | $21.11 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $15.44B | -54.2x | -1.35 | $241.71 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
| Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.76B | 34x | 1.57 | $518.59 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.9% Downside | Upgrade to Pro+ | |
| Regencell Bioscience Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.54B | -4,119.4x | $29.81 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.69B | -32.2x | -1.55 | $76.82 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
| Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.89B | -40.3x | -1.01 | $518.58 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
| Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.47B | 15.9x | 0.26 | $44.29 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
| Arrowhead Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.91B | 47.3x | 0.36 | $70.94 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
| Abivax ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.68B | -21.4x | 0.35 | $121.48 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.3% Upside | Upgrade to Pro+ | |
| Praxis Precision | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.57B | -25.1x | 1 | $339.93 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.18B | 112.8x | -2.41 | $58.50 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.9% Upside | Upgrade to Pro+ | |
| Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | $8.89B | -62.9x | 0.04 | $180.56 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.3% Upside | Upgrade to Pro+ | |
| Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.88B | -34.7x | -0.43 | $56.41 | 13.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
| ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.83B | 15.4x | -0.85 | $116.50 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
| Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.74B | -10.8x | 0.24 | $60.45 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | $8.61B | 20.4x | 0.05 | $41.64 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.1% Upside | Upgrade to Pro+ | |
| Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.23B | -17.8x | 0.4 | $104.75 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.7% Upside | Upgrade to Pro+ | |
| Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.06B | -10x | 0.43 | $65.37 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.9% Upside | Upgrade to Pro+ | |
| Immunitybio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.95B | -19.8x | -0.58 | $7.78 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Kymera | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.28B | -24x | 0.99 | $88.96 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.5% Upside | Upgrade to Pro+ | |
| Belite Bio ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.76B | -74.7x | 0.92 | $168.76 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.2% Upside | Upgrade to Pro+ | |
| Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.74B | -28.1x | 0.29 | $114.99 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0% Upside | Upgrade to Pro+ | |
| Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.68B | -50.6x | 0.34 | $105.44 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.7% Upside | Upgrade to Pro+ | |
| Apogee Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.53B | -17.1x | 0.9 | $89.28 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.2% Upside | Upgrade to Pro+ | |
| Centessa Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.12B | -27.1x | -1.06 | $39.61 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
| Terns Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.08B | -51.1x | -8.32 | $52.71 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.5% Upside | Upgrade to Pro+ | |
| Cogent Biosciences | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.86B | -14.2x | $36.29 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Celcuity | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.84B | -32.6x | 1 | $123.47 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.4% Upside | Upgrade to Pro+ | |
| CG Oncology | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.68B | 0.76 | $67.64 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | ||
| Erasca | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.65B | -41.2x | -1.22 | $18.19 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10% Upside | Upgrade to Pro+ | |
| Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.65B | -14.1x | 0.46 | $49.32 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.1% Upside | Upgrade to Pro+ | |
| Xenon Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.62B | -13.5x | 0.36 | $58.88 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.8% Upside | Upgrade to Pro+ | |
| Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.55B | -10.2x | 4.71 | $27.44 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.52B | 23.1x | -0.69 | $33.21 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.5% Upside | Upgrade to Pro+ | |
| Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.45B | -8.7x | 0.19 | $56.76 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.7% Upside | Upgrade to Pro+ | |
| Spyre Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.42B | -34.5x | -1.05 | $68.99 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.1% Upside | Upgrade to Pro+ | |
| Dianthus Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.17B | -22.6x | 0.45 | $95.76 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.4% Upside | Upgrade to Pro+ | |
| Amicus | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.54B | -164.4x | -3.2 | $14.46 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.3% Upside | Upgrade to Pro+ | |
| Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.17B | -8x | 0.26 | $39.76 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.11B | -11.1x | 0.05 | $35.45 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| NewAmsterdam Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.90B | -19.6x | -0.59 | $34.01 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.2% Upside | Upgrade to Pro+ |